CoChat

The Role of Fibrate Treatment in Dyslipidemia: An Overview

Katsiki, Niki, Nikolic, Dragana, Montalto, Giuseppe, Banach, Maciej, Mikhailidis, Dimitri P., Rizzo, Manfredi · 2013 · Current Pharmaceutical Design

The DOI matches its Crossref record.

Abstract

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributing to dyslipidemia management, particularly in patients with diabetes (DM) or the metabolic syndrome (MetS). Furthermore, fibrates exert beneficial effects on adipokines, inflammation and oxidative stress as well as neuroprotective properties. However, further studies are needed to define the role of fibrates in the prevention of CV events. We review the effects of fibrates on atherogenic dyslipidemia and CV risk reduction.

Overview

Integrity signals

Registry

Crossref · 10.2174/1381612811319170020

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 133

Metadata

Authors
Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D. P., & Rizzo, M.
Affiliations
Aristotle University of Thessaloniki (GR)
Venue
Current Pharmaceutical Design
Published
2013-04-01
Volume
19
Issue
17
Pages
3124-3131
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2040713479
Cited by
131
References
0
Citations by year
2026: 3 · 2025: 11 · 2024: 11 · 2023: 10 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 9 · 2018: 10 · 2017: 11 · 2016: 13 · 2015: 13 · 2014: 14 · 2013: 7
FWCI
15.43
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
fibrates, dyslipidemia, atherogenic dyslipidemia, PPAR ligands, small dense LDL, HDL cholesterol, triglycerides, lipid metabolism, cardiovascular risk reduction, diabetes mellitus, metabolic syndrome, adipokines, inflammation, oxidative stress, neuroprotection
MeSH terms
Animals, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Triglycerides, Dyslipidemias, Fibric Acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Fibrate Treatment in Dyslipidemia: An Overview. https://app.cochat.ai/papers/10.2174/1381612811319170020
The paper
Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D. P., & Rizzo, M. (2013). The Role of Fibrate Treatment in Dyslipidemia: An Overview. Current Pharmaceutical Design. https://doi.org/10.2174/1381612811319170020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.